SCHEMBL6206498

SCHEMBL6206498

Cc1ccccc1C1NCCCC1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 4/20 0.53
PRCP P42785 1/20 0.42
KDM1A O60341 1/20 0.39
HCRTR2 O43614 1/20 0.38
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38
SCN4A P35499 1/20 0.38
CHRM2 P08172 3/20 0.38
CHRM4 P08173 2/20 0.38
CHRM5 P08912 2/20 0.38
CHRM1 P11229 2/20 0.38
CHRM3 P20309 2/20 0.38
KDM4E B2RXH2 1/20 0.37
NPC1 O15118 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
HPGD P15428 1/20 0.37
MAPK1 P28482 1/20 0.37
CYP2C19 P33261 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22570096 0.78 TACR1 (0.46) CYP1A2CYP2D6CYP2C19
SCHEMBL22570100 0.78 TACR1 (0.46) CYP1A2CYP2D6CYP2C19
SCHEMBL21163277 0.78 TACR1 (0.46) CYP1A2CYP2D6CYP2C19
SCHEMBL15922404 0.78 TACR1 (0.46) CYP1A2CYP2D6CYP2C19
SCHEMBL14504584 0.78 TACR1 (0.46) CYP1A2CYP2D6CYP2C19
SCHEMBL25360423 0.78 TACR1 (0.46) CYP1A2CYP2D6CYP2C19
SCHEMBL29747537 0.78 HTR2C (0.52) HTR2CCHRM2CHRM4CHRM5CHRM1
SCHEMBL31444509 0.78 HTR2C (0.52) HTR2CCHRM2CHRM4CHRM5CHRM1
SCHEMBL29941194 0.78 HTR2C (0.52) HTR2CCHRM2CHRM4CHRM5CHRM1
SCHEMBL23323100 0.78 HTR2C (0.52) HTR2CCHRM2CHRM4CHRM5CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1487798-A4 SUBSTITUTED TETRAHYDROISOQUINOLINES AS C5A RECEPTOR MODULATORS NEUROGEN CORP (US) 2005-07-13 EP disclosed
US-6916830-B2 Substituted tetrahydroisoquinolines as C5a receptor modulators NEUROGEN CORPORATION (US) 2005-07-12 US disclosed
EP-1487798-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES AS C5A RECEPTOR MODULATORS Neurogen Corporation (US) 2004-12-22 EP disclosed
US-20040204446-A1 Nitrogen compounds such as N-(2-Fluoro-benzyl)-N-indan-2-yl-2-(3-methyl-2-o-tolyl-piperidin-1-yl) -acetamide, administered for prophylaxis arthritis, psoriasis, cardiovascular disorders, reperfusion injury or respiratory system disorders NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2004-10-14 US disclosed
US-6777422-B2 FOR TREATING A VARIETY OF INFLAMMATORY AND IMMUNE SYSTEM DISORDERS NEUROGEN CORP. 2004-08-17 US disclosed
US-20040006069-A1 Substituted tetrahydroisoquinolines as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2004-01-08 US disclosed
WO-2003082828-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES AS C5A RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2003-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006069-A1 Substituted tetrahydroisoquinolines as C5a receptor modulators C5AR1, C3AR1, C5AR2 HTR2C 142/4885PRCP 600/4885KDM1A 4215/4885
US-20040204446-A1 Nitrogen compounds such as N-(2-Fluoro-benzyl)-N-indan-2-yl-2-(3-methyl-2-o-tolyl-piperidin-1-yl) -acetamide, administered for prophylaxis arthritis, psoriasis, cardiovascular disorders, reperfusion injury or respiratory system disorders C5AR1, C3AR1, C5AR2 HTR2C 226/4885PRCP 2373/4885KDM1A 3057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.